After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for bankruptcy.
Fierce Biotech
信息服务
New York，New York 93,944 位关注者
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
关于我们
Fierce Biotech is the dominant B2B news brand for the industry. Our focus daily is on biotech and medtech companies. We cover the drug and device development universe as well as the financing, deals, IPOs and M&A that happen along the way and the people who move biotech and medtech forward. Our coverage also feeds longer-form content, podcasts and events. Our journalists track the news closely and have developed a network of contacts to bring you exclusives. Our coverage runs the gamut from good news to bad and flattering to unflattering to give readers and listeners an unvarnished view of what’s truly happening. Delivering news, revealing insights straight to your inboxes: https://fiercebiotech.questexinfo.com/loading.do?omedasite=LS_full. Our family of publications includes Fierce Biotech, Fierce Biotech PM Tracker, Fierce Medtech, Fierce Biotech Research, Fierce CRO, Fierce Life Sciences Weekly Digest and Fierce Cell & Gene Therapy. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Pharma news you can’t miss: https://www.dhirubhai.net/company/fierce-pharma For Healthcare news you can’t miss: https://www.dhirubhai.net/showcase/fierce-healthcare
- 网站
-
https://www.fiercebiotech.com/
Fierce Biotech的外部链接
- 所属行业
- 信息服务
- 规模
- 51-200 人
- 总部
- New York，New York
- 创立
- 2001
动态
-
Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company was "unwilling to engage with us to explore a potential combination,” Halozyme president and CEO Helen Torley said Nov. 22.
Halozyme withdraws $2B bid for Evotec after German biotech was 'unwilling to engage'
fiercebiotech.com
-
Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments.
Versant unveils Pep2Tango, a next-gen peptide biotech hoping to redefine obesity treatment
fiercebiotech.com
-
Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire Kate Therapeutics, according to the Big Pharma’s CEO.
Novartis, assessing peers’ muscular dystrophy failures, pens $1.1B deal for gene therapy biotech
fiercebiotech.com
-
With President-elect Trump’s incoming administration having suggested it could create a national bitcoin reserve, a selection of biotechs have announced their own plans to each create stockpiles of up to $1 million of the decentralized digital currency.
Biotechs go big for bitcoin: Trio of companies each plan to stash $1M as reserve
fiercebiotech.com
-
Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third quarter compared to the second.?
Amid broader uncertainty, biopharma market may have reached 'new norm': PitchBook
fiercebiotech.com
-
Neurogene hit investors with a one-two punch of bad news Monday, following up a premarket?setback?to its Rett syndrome program with a postmarket?revelation?that development of another gene therapy has hit a wall.
Neurogene stops Batten gene therapy after FDA denies request
fiercebiotech.com
-
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial.
Hidden data on obesity prospect wipe $12B off Amgen market cap
fiercebiotech.com
-
Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win.?
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
fiercebiotech.com
-
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease.
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
fiercebiotech.com